Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC abuse prevention in school

This article was originally published in The Tan Sheet

Executive Summary

New curriculum intended to curb abuse of over-the-counter and prescription medications will be added to the Drug Abuse Resistance Education America's law enforcement officer-led classes during the 2007-2008 school year, D.A.R.E. announces Dec. 12. The organization cites information from surveys by the Substance Abuse and Mental Health Services Administration and the Partnership for a Drug-Free America, which showed illegal drug use declining, but a "disturbing trend" of teen abuse of legal drugs, as the reason for adding the curriculum. "The rise in medicine abuse, both prescription and OTC, requires action, and that is why we have worked with the manufacturers of these medicines and our own experts in developing this new curriculum," D.A.R.E. President and CEO Charlie Parsons says...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel